ArticleDiscover oncology2026
A cross platform m7G risk score based on five gene pairs stratifies prognosis and stemness in acute myeloid leukemia.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AML exhibits marked heterogeneity in genetics, stemness, and treatment response. We profiled m7G regulator expression across multi-cohort AML transcriptomes and identified two m7G-related phenotypes with distinct survival and enrichment of adverse cytogenetics and primitive hierarchy. We then developed a cross-platform five-gene-pair m7G risk score using LASSO-Cox modeling. The score robustly stratified overall survival in TCGA and external cohorts (BEAT AML and GSE37642) and remained an independent prognostic factor. High risk was associated with increased leukemic stemness, including enrichment of HSC/MPP-like states in single-cell AML and higher scores in LSC+ fractions. The score also discriminated induction response (AUC 0.838) and increased in paired diagnosis-relapse samples, supporting relevance to chemoresistance. Drug sensitivity integration further nominated candidate compounds with preferential activity in high-risk AML. These findings connect m7G-related transcriptional programs to AML risk and provide a practical tool for refined prognostication and therapeutic prioritization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.